Mayo Clinic Study: Blood Marker Helps Estimate Cognitive Impairment Risk, Not Ready for Screening

A blood measure of phosphorylated tau 217 (p-tau217), combined with age, sex and APOE ε4 status, can estimate a cognitively healthy older adult’s risk of mild cognitive impairment over the next five to 10 years, Mayo Clinic researchers report this week in JAMA Neurology — with one large catch: age changes everything.

The study followed 2,178 cognitively unimpaired adults aged 60 to 90 from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Neuroimaging Initiative, Fox News reported. Participants gave blood for biomarker testing, underwent genetic testing and completed repeated cognitive assessments.

The goal, first author Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher, said in a news release, was “to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology.”

That matters because Alzheimer’s disease is defined by amyloid plaques and tau tangles accumulating in the brain. Until now, measuring that pathology reliably meant a PET scan or a spinal tap — expensive, invasive, and unavailable to most primary care clinics. A single blood draw is less invasive and potentially more scalable.

Protein Fragment Signals Alzheimer's Pathology Probability

  • p-tau217 is a protein fragment. When tau tangles form in the brain, a chemically modified version — phosphorylated tau — leaks into the blood. Higher levels signal more Alzheimer’s-type pathology.
  • The model gives a probability, not a diagnosis. A positive or high result changes no treatment today; there is no approved therapy for people without symptoms who carry brain pathology.
  • Most people with elevated risk never develop impairment. Even the highest numbers here leave the majority unaffected over the study window.

The Numbers: Age Outweighs Genetics

Age dominated the risk model. At the same elevated p-tau217 level, a 65-year-old faced a roughly 6% estimated five-year risk of mild cognitive impairment; an 85-year-old faced 37%, the researchers found, as Fox News reported. The APOE ε4 genetic variant — long the best-known risk marker — carried only a modest association once p-tau217 was accounted for.

Blood test for older adults
Photo: Medical Daily

To illustrate how the model works, Medical Daily walked through a specific case: a 75-year-old woman lacking APOE ε4 had an estimated five-year risk of mild cognitive impairment of roughly 5% at a relatively low p-tau217 level, climbing to 16% at a higher level. Over 10 years, those estimates rose from 12% to 35%. Even the higher figure leaves a better-than-even chance of remaining cognitively intact.

Scenario (from the published model) 5-year risk 10-year risk
75-year-old woman, no APOE ε4, low p-tau217 ~5% 12%
75-year-old woman, no APOE ε4, higher p-tau217 16% 35%
65-year-old at elevated p-tau217 level ~6% Not given
85-year-old at the same elevated p-tau217 level 37% Not given

Independent work points the same direction. Another study, involving 2,684 older adults with no cognitive impairment and published in JAMA — which Medical Daily referenced — found that those with very high p-tau217 levels faced an estimated 38% likelihood of developing cognitive impairment within five years.

What the Test Measures, and How

Mechanistically, p-tau217 detection works because tau protein modified at specific phosphorylation sites — the threonine-217 position — is released into cerebrospinal fluid and plasma as tangles develop. In plain terms: the pathology leaves a chemical calling card in the blood, and modern immunoassays can read it.

Senior author Clifford Jack Jr., a Mayo Clinic neuroradiologist, put it simply: “The test tells you, just by taking a blood sample, whether someone has that pathology in the brain,” he told Fox News Digital. Higher levels of the pathology, he added, are associated with a greater risk of progressing from normal cognition to impairment.

Mayo Clinic Study: Blood Marker Helps Estimate Cognitive Impairment Risk, Not Ready for Screening
Photo: MedPage Today

A practical caveat, flagged by Medical Daily: different commercial p-tau217 assays may produce different values, so the Mayo risk estimates may not transfer directly from one laboratory to another.

Why the Researchers Say Don’t Test Yet

Despite the model’s precision, the team is explicit that routine screening of people without cognitive symptoms is not recommended. The logic is treatment-driven, not statistical.

“There’s no treatment that’s been approved for people who are [asymptomatic] but have the disease in the brain. Therefore, there’s no reason to do the test. … The results of the test would not change your medical management at all since there’s no treatment available.”

— Clifford Jack Jr., Mayo Clinic neuroradiologist, in remarks to Fox News Digital.

If investigational preventive treatments prove effective at delaying or preventing decline, the calculus changes. “If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment,” Jack said.

Medical Daily’s reporting adds an equity note: adults with a family history of dementia are among those most likely to seek testing, yet ordering a p-tau217 test without symptoms carries the risk of anxiety without any change in care. Ronald Petersen, a Mayo Clinic neurologist and director of the Mayo Clinic Study of Aging, is among the researchers associated with the work.

The study also carries geographic limits. The risk estimates were developed within the Mayo Clinic Study of Aging, drawn from southeast Minnesota — a population Jack conceded “is not representative of the entire United States.” The methods could be applied elsewhere, but the findings need replication outside the region.

Medical Daily noted the composition of the participant groups: 1,644 adults between 60 and 90 years old drawn from the Mayo Clinic Study of Aging, plus validation in a separate group of 534 individuals.

Access and the Regulatory Path Ahead

The gap between a validated risk model and routine clinical availability runs through regulators. None of the outlets reported imminent regulatory submissions specific to this model.

One thing the study does not establish, Fox News noted: that routine blood testing prevents dementia or improves clinical outcomes. Jack also cautioned that some people with Alzheimer’s-related pathology never develop symptoms in their lifetime, and others die of another cause first. A low estimate does not rule out decline, and a high one does not guarantee it.

Testing Not Recommended for Asymptomatic People

No source recommends p-tau217 testing for people without cognitive symptoms at this time; the researchers themselves say the model is not ready for routine screening of the asymptomatic.

Older adults with memory concerns should see a primary care clinician to check for treatable causes of cognitive change and discuss whether further evaluation is needed, as Medical Daily advised. People with a family history of dementia who feel compelled to seek testing should discuss with a clinician whether a result would actually change their care today.

Model Awaits Treatment Approval for Clinical Use

The model’s real value may be prospective: anchoring future decisions, in the clinic and in trials of preventive drugs, on individualized probabilities rather than a positive-versus-negative verdict. What could flip the switch is a regulator approving a treatment for asymptomatic people with brain pathology. Until then, the marker sits ready — and unused.

References

  • Mayo Clinic p-tau217 study, JAMA Neurology — Blood levels of p-tau217 linked with 5- and 10-year risks of cognitive impairment
  • Independent JAMA study of 2,684 cognitively unimpaired adults — JAMA
  • Fox News Digital, Melissa Rudy, “Alzheimer’s blood marker could predict cognitive decline risks,” Mayo Clinic study coverage, Nov. 2026
  • Medical Daily, “Mayo Clinic Blood Test Model Estimates Five- and 10-Year Risk of Memory Impairment in Cognitively Healthy Older Adults,” Nov. 2026
  • MedPage Today, “Blood Test Predicts Dementia; Diabetes and Alzheimer’s,” Nov. 2026

Disclaimer: This article is a factual report on a peer-reviewed study and is not medical advice. Diagnosis and testing decisions, including for memory concerns, should be made with a qualified clinician.

Photo of author

Health Desk

Health Desk at Archyde.

Groen Members to Vote on Nuclear Power as Transition Technology

Twins Sign Sonny Gray to 2-Year, $55M Deal With Opt-Out